Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
Related Posts
Art Cashin, New York Stock Exchange fixture for decades, dies at age 83
Art Cashin was UBS’ director of floor operations at the NYSE and a man The Washington Post called “Wall Street’s version of Walter Cronkite.”
The Federal Reserve holds interest rates steady: Here’s what that means for your money
The Federal paused rate cuts after its first meeting of the year — here’s what that means for your credit card, mortgage rate, auto loan […]
Inside GM’s decade-long battle to revive Cadillac as the quintessential American luxury car brand
Here’s how the brand is trying to get its portfolio back into shape and boost its status in the competitive luxury vehicle market.